So what will our news be for september 12th? I
Post# of 148190
(Total Views: 344)
Posted On: 09/09/2019 8:35:38 AM
So what will our news be for september 12th?
I’m betting on a Bayer partnership for metastatic colorectal cancer.
Only recently (july 18th) Bayer, Bristol Meyers Squibb and Ono Pharma released partnering news for a combination therapy for metastatic colorectal cancer.
(https://news.bms.com/press-release/partnering-news/bayer-bristol-myers-squibb-and-ono-pharmaceutical-enter-clinical-colla)
This is what Scott Z. Fields, M.D., senior vice president and head of Oncology Development at Bayer's Pharmaceuticals Division stated:
“Regorafenib as monotherapy has demonstrated an overall survival benefit versus placebo in the pivotal Phase III CORRECT study and has shown activity irrespective of micro-satellite status in a retrospective analysis from this study, though with limited responses observed. Despite progress in the treatment of CRC, including the advance of effective immuno-oncology (I-O) treatments for certain subsets of CRC, around 95% of mCRC patients have MSS tumors, for which I-O monotherapy treatment approaches have shown limited activity. Thus, the need for additional treatment options including combination approaches remains high”
Regorafenib (Bayer) and nivolumab (BMS/OP) both have SAE’s thus it’s no surprise Bayer would like to partner with Cydy given Leronlimabs safety profile. And like SF stated: the need for additional treatment options including combination approaches remains high.
Yes, I’m somehow expect an agreement with Bayer to be announced.
I’m betting on a Bayer partnership for metastatic colorectal cancer.
Only recently (july 18th) Bayer, Bristol Meyers Squibb and Ono Pharma released partnering news for a combination therapy for metastatic colorectal cancer.
(https://news.bms.com/press-release/partnering-news/bayer-bristol-myers-squibb-and-ono-pharmaceutical-enter-clinical-colla)
This is what Scott Z. Fields, M.D., senior vice president and head of Oncology Development at Bayer's Pharmaceuticals Division stated:
“Regorafenib as monotherapy has demonstrated an overall survival benefit versus placebo in the pivotal Phase III CORRECT study and has shown activity irrespective of micro-satellite status in a retrospective analysis from this study, though with limited responses observed. Despite progress in the treatment of CRC, including the advance of effective immuno-oncology (I-O) treatments for certain subsets of CRC, around 95% of mCRC patients have MSS tumors, for which I-O monotherapy treatment approaches have shown limited activity. Thus, the need for additional treatment options including combination approaches remains high”
Regorafenib (Bayer) and nivolumab (BMS/OP) both have SAE’s thus it’s no surprise Bayer would like to partner with Cydy given Leronlimabs safety profile. And like SF stated: the need for additional treatment options including combination approaches remains high.
Yes, I’m somehow expect an agreement with Bayer to be announced.
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼